

Global Radionuclide-conjugated Drugs Market Growth (Status and Outlook) 2024-2030

<https://marketpublishers.com/r/GF0603CB6413EN.html>

Date: July 2024

Pages: 140

Price: US\$ 3,660.00 (Single User License)

ID: GF0603CB6413EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

The global Radionuclide-conjugated Drugs market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the "Radionuclide-conjugated Drugs Industry Forecast" looks at past sales and reviews total world Radionuclide-conjugated Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Radionuclide-conjugated Drugs sales for 2023 through 2029. With Radionuclide-conjugated Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Radionuclide-conjugated Drugs industry.

This Insight Report provides a comprehensive analysis of the global Radionuclide-conjugated Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide-conjugated Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique

position in an accelerating global Radionuclide-conjugated Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide-conjugated Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide-conjugated Drugs.

United States market for Radionuclide-conjugated Drugs is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Radionuclide-conjugated Drugs is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Radionuclide-conjugated Drugs is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Radionuclide-conjugated Drugs players cover Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide-conjugated Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:

Beta-emitting

Targeted Alpha Therapy

Segmentation by Application:

Solid Tumor

Non Hodgkin Lymphoma

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Segmentation by Type:

Beta-emitting

Targeted Alpha Therapy

Segmentation by Application:

Solid Tumor

Non Hodgkin Lymphoma

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Bayer

Novartis

Lantheus

Aurobindo Pharma

Mundipharma

China Isotope & Radiation

Curium Pharmaceuticals

Gilead Sciences

Clarity Pharmaceuticals

Curasight

Nordic Nanovector

Philogen

RadioMedix

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Radionuclide-conjugated Drugs Market Size 2019-2030
 - 2.1.2 Radionuclide-conjugated Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030)
 - 2.1.3 World Current & Future Analysis for Radionuclide-conjugated Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 Radionuclide-conjugated Drugs Segment by Type
 - 2.2.1 Beta-emitting
 - 2.2.2 Targeted Alpha Therapy
- 2.3 Radionuclide-conjugated Drugs Market Size by Type
 - 2.3.1 Radionuclide-conjugated Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
 - 2.3.2 Global Radionuclide-conjugated Drugs Market Size Market Share by Type (2019-2024)
- 2.4 Radionuclide-conjugated Drugs Segment by Application
 - 2.4.1 Solid Tumor
 - 2.4.2 Non Hodgkin Lymphoma
- 2.5 Radionuclide-conjugated Drugs Market Size by Application
 - 2.5.1 Radionuclide-conjugated Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
 - 2.5.2 Global Radionuclide-conjugated Drugs Market Size Market Share by Application (2019-2024)

3 RADIONUCLIDE-CONJUGATED DRUGS MARKET SIZE BY PLAYER

- 3.1 Radionuclide-conjugated Drugs Market Size Market Share by Player
 - 3.1.1 Global Radionuclide-conjugated Drugs Revenue by Player (2019-2024)
 - 3.1.2 Global Radionuclide-conjugated Drugs Revenue Market Share by Player (2019-2024)
- 3.2 Global Radionuclide-conjugated Drugs Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 RADIONUCLIDE-CONJUGATED DRUGS BY REGION

- 4.1 Radionuclide-conjugated Drugs Market Size by Region (2019-2024)
- 4.2 Global Radionuclide-conjugated Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Radionuclide-conjugated Drugs Market Size Growth (2019-2024)
- 4.4 APAC Radionuclide-conjugated Drugs Market Size Growth (2019-2024)
- 4.5 Europe Radionuclide-conjugated Drugs Market Size Growth (2019-2024)
- 4.6 Middle East & Africa Radionuclide-conjugated Drugs Market Size Growth (2019-2024)

5 AMERICAS

- 5.1 Americas Radionuclide-conjugated Drugs Market Size by Country (2019-2024)
- 5.2 Americas Radionuclide-conjugated Drugs Market Size by Type (2019-2024)
- 5.3 Americas Radionuclide-conjugated Drugs Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Radionuclide-conjugated Drugs Market Size by Region (2019-2024)
- 6.2 APAC Radionuclide-conjugated Drugs Market Size by Type (2019-2024)
- 6.3 APAC Radionuclide-conjugated Drugs Market Size by Application (2019-2024)

- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Radionuclide-conjugated Drugs Market Size by Country (2019-2024)
- 7.2 Europe Radionuclide-conjugated Drugs Market Size by Type (2019-2024)
- 7.3 Europe Radionuclide-conjugated Drugs Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Radionuclide-conjugated Drugs by Region (2019-2024)
- 8.2 Middle East & Africa Radionuclide-conjugated Drugs Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Radionuclide-conjugated Drugs Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL RADIONUCLIDE-CONJUGATED DRUGS MARKET FORECAST

- 10.1 Global Radionuclide-conjugated Drugs Forecast by Region (2025-2030)
 - 10.1.1 Global Radionuclide-conjugated Drugs Forecast by Region (2025-2030)
 - 10.1.2 Americas Radionuclide-conjugated Drugs Forecast
 - 10.1.3 APAC Radionuclide-conjugated Drugs Forecast
 - 10.1.4 Europe Radionuclide-conjugated Drugs Forecast
 - 10.1.5 Middle East & Africa Radionuclide-conjugated Drugs Forecast
- 10.2 Americas Radionuclide-conjugated Drugs Forecast by Country (2025-2030)
 - 10.2.1 United States Market Radionuclide-conjugated Drugs Forecast
 - 10.2.2 Canada Market Radionuclide-conjugated Drugs Forecast
 - 10.2.3 Mexico Market Radionuclide-conjugated Drugs Forecast
 - 10.2.4 Brazil Market Radionuclide-conjugated Drugs Forecast
- 10.3 APAC Radionuclide-conjugated Drugs Forecast by Region (2025-2030)
 - 10.3.1 China Radionuclide-conjugated Drugs Market Forecast
 - 10.3.2 Japan Market Radionuclide-conjugated Drugs Forecast
 - 10.3.3 Korea Market Radionuclide-conjugated Drugs Forecast
 - 10.3.4 Southeast Asia Market Radionuclide-conjugated Drugs Forecast
 - 10.3.5 India Market Radionuclide-conjugated Drugs Forecast
 - 10.3.6 Australia Market Radionuclide-conjugated Drugs Forecast
- 10.4 Europe Radionuclide-conjugated Drugs Forecast by Country (2025-2030)
 - 10.4.1 Germany Market Radionuclide-conjugated Drugs Forecast
 - 10.4.2 France Market Radionuclide-conjugated Drugs Forecast
 - 10.4.3 UK Market Radionuclide-conjugated Drugs Forecast
 - 10.4.4 Italy Market Radionuclide-conjugated Drugs Forecast
 - 10.4.5 Russia Market Radionuclide-conjugated Drugs Forecast
- 10.5 Middle East & Africa Radionuclide-conjugated Drugs Forecast by Region (2025-2030)
 - 10.5.1 Egypt Market Radionuclide-conjugated Drugs Forecast
 - 10.5.2 South Africa Market Radionuclide-conjugated Drugs Forecast
 - 10.5.3 Israel Market Radionuclide-conjugated Drugs Forecast
 - 10.5.4 Turkey Market Radionuclide-conjugated Drugs Forecast
- 10.6 Global Radionuclide-conjugated Drugs Forecast by Type (2025-2030)
- 10.7 Global Radionuclide-conjugated Drugs Forecast by Application (2025-2030)
 - 10.7.1 GCC Countries Market Radionuclide-conjugated Drugs Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Bayer
 - 11.1.1 Bayer Company Information
 - 11.1.2 Bayer Radionuclide-conjugated Drugs Product Offered

11.1.3 Bayer Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.1.4 Bayer Main Business Overview

11.1.5 Bayer Latest Developments

11.2 Novartis

11.2.1 Novartis Company Information

11.2.2 Novartis Radionuclide-conjugated Drugs Product Offered

11.2.3 Novartis Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.2.4 Novartis Main Business Overview

11.2.5 Novartis Latest Developments

11.3 Lantheus

11.3.1 Lantheus Company Information

11.3.2 Lantheus Radionuclide-conjugated Drugs Product Offered

11.3.3 Lantheus Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.3.4 Lantheus Main Business Overview

11.3.5 Lantheus Latest Developments

11.4 Aurobindo Pharma

11.4.1 Aurobindo Pharma Company Information

11.4.2 Aurobindo Pharma Radionuclide-conjugated Drugs Product Offered

11.4.3 Aurobindo Pharma Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.4.4 Aurobindo Pharma Main Business Overview

11.4.5 Aurobindo Pharma Latest Developments

11.5 Mundipharma

11.5.1 Mundipharma Company Information

11.5.2 Mundipharma Radionuclide-conjugated Drugs Product Offered

11.5.3 Mundipharma Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.5.4 Mundipharma Main Business Overview

11.5.5 Mundipharma Latest Developments

11.6 China Isotope & Radiation

11.6.1 China Isotope & Radiation Company Information

11.6.2 China Isotope & Radiation Radionuclide-conjugated Drugs Product Offered

11.6.3 China Isotope & Radiation Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.6.4 China Isotope & Radiation Main Business Overview

11.6.5 China Isotope & Radiation Latest Developments

11.7 Curium Pharmaceuticals

11.7.1 Curium Pharmaceuticals Company Information

11.7.2 Curium Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

11.7.3 Curium Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.7.4 Curium Pharmaceuticals Main Business Overview

11.7.5 Curium Pharmaceuticals Latest Developments

11.8 Gilead Sciences

11.8.1 Gilead Sciences Company Information

11.8.2 Gilead Sciences Radionuclide-conjugated Drugs Product Offered

11.8.3 Gilead Sciences Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.8.4 Gilead Sciences Main Business Overview

11.8.5 Gilead Sciences Latest Developments

11.9 Clarity Pharmaceuticals

11.9.1 Clarity Pharmaceuticals Company Information

11.9.2 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

11.9.3 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.9.4 Clarity Pharmaceuticals Main Business Overview

11.9.5 Clarity Pharmaceuticals Latest Developments

11.10 Curasight

11.10.1 Curasight Company Information

11.10.2 Curasight Radionuclide-conjugated Drugs Product Offered

11.10.3 Curasight Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.10.4 Curasight Main Business Overview

11.10.5 Curasight Latest Developments

11.11 Nordic Nanovector

11.11.1 Nordic Nanovector Company Information

11.11.2 Nordic Nanovector Radionuclide-conjugated Drugs Product Offered

11.11.3 Nordic Nanovector Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)

11.11.4 Nordic Nanovector Main Business Overview

11.11.5 Nordic Nanovector Latest Developments

11.12 Philogen

11.12.1 Philogen Company Information

11.12.2 Philogen Radionuclide-conjugated Drugs Product Offered

11.12.3 Philogen Radionuclide-conjugated Drugs Revenue, Gross Margin and Market

Share (2019-2024)

11.12.4 Philogen Main Business Overview

11.12.5 Philogen Latest Developments

11.13 RadioMedix

11.13.1 RadioMedix Company Information

11.13.2 RadioMedix Radionuclide-conjugated Drugs Product Offered

11.13.3 RadioMedix Radionuclide-conjugated Drugs Revenue, Gross Margin and

Market Share (2019-2024)

11.13.4 RadioMedix Main Business Overview

11.13.5 RadioMedix Latest Developments

11.14 Telix Pharmaceuticals

11.14.1 Telix Pharmaceuticals Company Information

11.14.2 Telix Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

11.14.3 Telix Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross

Margin and Market Share (2019-2024)

11.14.4 Telix Pharmaceuticals Main Business Overview

11.14.5 Telix Pharmaceuticals Latest Developments

11.15 Orano Med

11.15.1 Orano Med Company Information

11.15.2 Orano Med Radionuclide-conjugated Drugs Product Offered

11.15.3 Orano Med Radionuclide-conjugated Drugs Revenue, Gross Margin and

Market Share (2019-2024)

11.15.4 Orano Med Main Business Overview

11.15.5 Orano Med Latest Developments

11.16 Actinium Pharmaceuticals

11.16.1 Actinium Pharmaceuticals Company Information

11.16.2 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

11.16.3 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross

Margin and Market Share (2019-2024)

11.16.4 Actinium Pharmaceuticals Main Business Overview

11.16.5 Actinium Pharmaceuticals Latest Developments

11.17 Y-mAbs Therapeutics

11.17.1 Y-mAbs Therapeutics Company Information

11.17.2 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product Offered

11.17.3 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Revenue, Gross Margin

and Market Share (2019-2024)

11.17.4 Y-mAbs Therapeutics Main Business Overview

11.17.5 Y-mAbs Therapeutics Latest Developments

11.18 Fusion Pharmaceuticals

- 11.18.1 Fusion Pharmaceuticals Company Information
- 11.18.2 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product Offered
- 11.18.3 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.18.4 Fusion Pharmaceuticals Main Business Overview
- 11.18.5 Fusion Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Radionuclide-conjugated Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & (\$ millions)
- Table 2. Radionuclide-conjugated Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of Beta-emitting
- Table 4. Major Players of Targeted Alpha Therapy
- Table 5. Radionuclide-conjugated Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & (\$ millions)
- Table 6. Global Radionuclide-conjugated Drugs Market Size by Type (2019-2024) & (\$ millions)
- Table 7. Global Radionuclide-conjugated Drugs Market Size Market Share by Type (2019-2024)
- Table 8. Radionuclide-conjugated Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & (\$ millions)
- Table 9. Global Radionuclide-conjugated Drugs Market Size by Application (2019-2024) & (\$ millions)
- Table 10. Global Radionuclide-conjugated Drugs Market Size Market Share by Application (2019-2024)
- Table 11. Global Radionuclide-conjugated Drugs Revenue by Player (2019-2024) & (\$ millions)
- Table 12. Global Radionuclide-conjugated Drugs Revenue Market Share by Player (2019-2024)
- Table 13. Radionuclide-conjugated Drugs Key Players Head office and Products Offered
- Table 14. Radionuclide-conjugated Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- Table 15. New Products and Potential Entrants
- Table 16. Mergers & Acquisitions, Expansion
- Table 17. Global Radionuclide-conjugated Drugs Market Size by Region (2019-2024) & (\$ millions)
- Table 18. Global Radionuclide-conjugated Drugs Market Size Market Share by Region (2019-2024)
- Table 19. Global Radionuclide-conjugated Drugs Revenue by Country/Region (2019-2024) & (\$ millions)
- Table 20. Global Radionuclide-conjugated Drugs Revenue Market Share by

Country/Region (2019-2024)

Table 21. Americas Radionuclide-conjugated Drugs Market Size by Country (2019-2024) & (\$ millions)

Table 22. Americas Radionuclide-conjugated Drugs Market Size Market Share by Country (2019-2024)

Table 23. Americas Radionuclide-conjugated Drugs Market Size by Type (2019-2024) & (\$ millions)

Table 24. Americas Radionuclide-conjugated Drugs Market Size Market Share by Type (2019-2024)

Table 25. Americas Radionuclide-conjugated Drugs Market Size by Application (2019-2024) & (\$ millions)

Table 26. Americas Radionuclide-conjugated Drugs Market Size Market Share by Application (2019-2024)

Table 27. APAC Radionuclide-conjugated Drugs Market Size by Region (2019-2024) & (\$ millions)

Table 28. APAC Radionuclide-conjugated Drugs Market Size Market Share by Region (2019-2024)

Table 29. APAC Radionuclide-conjugated Drugs Market Size by Type (2019-2024) & (\$ millions)

Table 30. APAC Radionuclide-conjugated Drugs Market Size by Application (2019-2024) & (\$ millions)

Table 31. Europe Radionuclide-conjugated Drugs Market Size by Country (2019-2024) & (\$ millions)

Table 32. Europe Radionuclide-conjugated Drugs Market Size Market Share by Country (2019-2024)

Table 33. Europe Radionuclide-conjugated Drugs Market Size by Type (2019-2024) & (\$ millions)

Table 34. Europe Radionuclide-conjugated Drugs Market Size by Application (2019-2024) & (\$ millions)

Table 35. Middle East & Africa Radionuclide-conjugated Drugs Market Size by Region (2019-2024) & (\$ millions)

Table 36. Middle East & Africa Radionuclide-conjugated Drugs Market Size by Type (2019-2024) & (\$ millions)

Table 37. Middle East & Africa Radionuclide-conjugated Drugs Market Size by Application (2019-2024) & (\$ millions)

Table 38. Key Market Drivers & Growth Opportunities of Radionuclide-conjugated Drugs

Table 39. Key Market Challenges & Risks of Radionuclide-conjugated Drugs

Table 40. Key Industry Trends of Radionuclide-conjugated Drugs

Table 41. Global Radionuclide-conjugated Drugs Market Size Forecast by Region

(2025-2030) & (\$ millions)

Table 42. Global Radionuclide-conjugated Drugs Market Size Market Share Forecast by Region (2025-2030)

Table 43. Global Radionuclide-conjugated Drugs Market Size Forecast by Type (2025-2030) & (\$ millions)

Table 44. Global Radionuclide-conjugated Drugs Market Size Forecast by Application (2025-2030) & (\$ millions)

Table 45. Bayer Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 46. Bayer Radionuclide-conjugated Drugs Product Offered

Table 47. Bayer Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 48. Bayer Main Business

Table 49. Bayer Latest Developments

Table 50. Novartis Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 51. Novartis Radionuclide-conjugated Drugs Product Offered

Table 52. Novartis Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 53. Novartis Main Business

Table 54. Novartis Latest Developments

Table 55. Lantheus Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 56. Lantheus Radionuclide-conjugated Drugs Product Offered

Table 57. Lantheus Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 58. Lantheus Main Business

Table 59. Lantheus Latest Developments

Table 60. Aurobindo Pharma Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 61. Aurobindo Pharma Radionuclide-conjugated Drugs Product Offered

Table 62. Aurobindo Pharma Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 63. Aurobindo Pharma Main Business

Table 64. Aurobindo Pharma Latest Developments

Table 65. Mundipharma Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 66. Mundipharma Radionuclide-conjugated Drugs Product Offered

Table 67. Mundipharma Radionuclide-conjugated Drugs Revenue (\$ million), Gross

Margin and Market Share (2019-2024)

Table 68. Mundipharma Main Business

Table 69. Mundipharma Latest Developments

Table 70. China Isotope & Radiation Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 71. China Isotope & Radiation Radionuclide-conjugated Drugs Product Offered

Table 72. China Isotope & Radiation Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 73. China Isotope & Radiation Main Business

Table 74. China Isotope & Radiation Latest Developments

Table 75. Curium Pharmaceuticals Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 76. Curium Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

Table 77. Curium Pharmaceuticals Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 78. Curium Pharmaceuticals Main Business

Table 79. Curium Pharmaceuticals Latest Developments

Table 80. Gilead Sciences Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 81. Gilead Sciences Radionuclide-conjugated Drugs Product Offered

Table 82. Gilead Sciences Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 83. Gilead Sciences Main Business

Table 84. Gilead Sciences Latest Developments

Table 85. Clarity Pharmaceuticals Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 86. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

Table 87. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 88. Clarity Pharmaceuticals Main Business

Table 89. Clarity Pharmaceuticals Latest Developments

Table 90. Curasight Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 91. Curasight Radionuclide-conjugated Drugs Product Offered

Table 92. Curasight Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 93. Curasight Main Business

Table 94. Curasight Latest Developments

Table 95. Nordic Nanovector Details, Company Type, Radionuclide-conjugated Drugs

Area Served and Its Competitors

Table 96. Nordic Nanovector Radionuclide-conjugated Drugs Product Offered

Table 97. Nordic Nanovector Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 98. Nordic Nanovector Main Business

Table 99. Nordic Nanovector Latest Developments

Table 100. Philogen Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 101. Philogen Radionuclide-conjugated Drugs Product Offered

Table 102. Philogen Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 103. Philogen Main Business

Table 104. Philogen Latest Developments

Table 105. RadioMedix Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 106. RadioMedix Radionuclide-conjugated Drugs Product Offered

Table 107. RadioMedix Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 108. RadioMedix Main Business

Table 109. RadioMedix Latest Developments

Table 110. Telix Pharmaceuticals Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 111. Telix Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

Table 112. Telix Pharmaceuticals Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 113. Telix Pharmaceuticals Main Business

Table 114. Telix Pharmaceuticals Latest Developments

Table 115. Orano Med Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 116. Orano Med Radionuclide-conjugated Drugs Product Offered

Table 117. Orano Med Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 118. Orano Med Main Business

Table 119. Orano Med Latest Developments

Table 120. Actinium Pharmaceuticals Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 121. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

Table 122. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 123. Actinium Pharmaceuticals Main Business

Table 124. Actinium Pharmaceuticals Latest Developments

Table 125. Y-mAbs Therapeutics Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 126. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product Offered

Table 127. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 128. Y-mAbs Therapeutics Main Business

Table 129. Y-mAbs Therapeutics Latest Developments

Table 130. Fusion Pharmaceuticals Details, Company Type, Radionuclide-conjugated Drugs Area Served and Its Competitors

Table 131. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product Offered

Table 132. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 133. Fusion Pharmaceuticals Main Business

Table 134. Fusion Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Radionuclide-conjugated Drugs Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Radionuclide-conjugated Drugs Market Size Growth Rate 2019-2030 (\$ millions)
- Figure 6. Radionuclide-conjugated Drugs Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 7. Radionuclide-conjugated Drugs Sales Market Share by Country/Region (2023)
- Figure 8. Radionuclide-conjugated Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 9. Global Radionuclide-conjugated Drugs Market Size Market Share by Type in 2023
- Figure 10. Radionuclide-conjugated Drugs in Solid Tumor
- Figure 11. Global Radionuclide-conjugated Drugs Market: Solid Tumor (2019-2024) & (\$ millions)
- Figure 12. Radionuclide-conjugated Drugs in Non Hodgkin Lymphoma
- Figure 13. Global Radionuclide-conjugated Drugs Market: Non Hodgkin Lymphoma (2019-2024) & (\$ millions)
- Figure 14. Global Radionuclide-conjugated Drugs Market Size Market Share by Application in 2023
- Figure 15. Global Radionuclide-conjugated Drugs Revenue Market Share by Player in 2023
- Figure 16. Global Radionuclide-conjugated Drugs Market Size Market Share by Region (2019-2024)
- Figure 17. Americas Radionuclide-conjugated Drugs Market Size 2019-2024 (\$ millions)
- Figure 18. APAC Radionuclide-conjugated Drugs Market Size 2019-2024 (\$ millions)
- Figure 19. Europe Radionuclide-conjugated Drugs Market Size 2019-2024 (\$ millions)
- Figure 20. Middle East & Africa Radionuclide-conjugated Drugs Market Size 2019-2024 (\$ millions)
- Figure 21. Americas Radionuclide-conjugated Drugs Value Market Share by Country in 2023
- Figure 22. United States Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)
- Figure 23. Canada Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$

millions)

Figure 24. Mexico Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 25. Brazil Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 26. APAC Radionuclide-conjugated Drugs Market Size Market Share by Region in 2023

Figure 27. APAC Radionuclide-conjugated Drugs Market Size Market Share by Type (2019-2024)

Figure 28. APAC Radionuclide-conjugated Drugs Market Size Market Share by Application (2019-2024)

Figure 29. China Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 30. Japan Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 31. South Korea Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 32. Southeast Asia Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 33. India Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 34. Australia Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 35. Europe Radionuclide-conjugated Drugs Market Size Market Share by Country in 2023

Figure 36. Europe Radionuclide-conjugated Drugs Market Size Market Share by Type (2019-2024)

Figure 37. Europe Radionuclide-conjugated Drugs Market Size Market Share by Application (2019-2024)

Figure 38. Germany Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 39. France Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 40. UK Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 41. Italy Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 42. Russia Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 43. Middle East & Africa Radionuclide-conjugated Drugs Market Size Market Share by Region (2019-2024)

Figure 44. Middle East & Africa Radionuclide-conjugated Drugs Market Size Market Share by Type (2019-2024)

Figure 45. Middle East & Africa Radionuclide-conjugated Drugs Market Size Market Share by Application (2019-2024)

Figure 46. Egypt Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 47. South Africa Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 48. Israel Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 49. Turkey Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 50. GCC Countries Radionuclide-conjugated Drugs Market Size Growth 2019-2024 (\$ millions)

Figure 51. Americas Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 52. APAC Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 53. Europe Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 54. Middle East & Africa Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 55. United States Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 56. Canada Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 57. Mexico Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 58. Brazil Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 59. China Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 60. Japan Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 61. Korea Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 62. Southeast Asia Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 63. India Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 64. Australia Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 65. Germany Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 66. France Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 67. UK Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 68. Italy Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 69. Russia Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 70. Egypt Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 71. South Africa Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 72. Israel Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 73. Turkey Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 74. GCC Countries Radionuclide-conjugated Drugs Market Size 2025-2030 (\$ millions)

Figure 75. Global Radionuclide-conjugated Drugs Market Size Market Share Forecast by Type (2025-2030)

Figure 76. Global Radionuclide-conjugated Drugs Market Size Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Radionuclide-conjugated Drugs Market Growth (Status and Outlook) 2024-2030

Product link: <https://marketpublishers.com/r/GF0603CB6413EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF0603CB6413EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970